Loading organizations...
Clinical-stage biotechnology company developing gene modulation therapies using epigenetic regulation for prevalent diseases.
Epigenic Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, that develops next-generation gene modulation therapies using epigenetic regulation to treat prevalent chronic diseases. The organization utilizes its proprietary EPIREG technology to precisely modulate gene expression for the durable silencing of target genes, offering an alternative to traditional gene editing. Its pipeline targets a range of conditions, including metabolic, cardiovascular, viral hepatitis, ocular, and autoimmune diseases. The enterprise has raised at least $92 million in total funding, which includes a $32 million Series A round and a recent $60 million Series B financing to accelerate clinical development. These equity rounds were backed by prominent venture capital firms such as Qiming Venture Partners, OrbiMed, Lapam Capital, and Morningside Venture Capital. Epigenic Therapeutics was founded in 2021 by Bob Zhang and a team of scientists.
Epigenic Therapeutics has raised $112.0M across 3 funding rounds.
Epigenic Therapeutics has raised $112.0M in total across 3 funding rounds.
Epigenic Therapeutics has raised $112.0M in total across 3 funding rounds.
Epigenic Therapeutics's investors include Zhihua Yu, OrbiMed, IFSC, Qiming Venture Partners, Chen Kan, Morningside, FountainBridge Capital, Kingray Capital, Michael Xue, Trinity Innovation Fund.
Epigenic Therapeutics is a Shanghai-based biotechnology company developing next-generation gene modulation therapies using epigenome regulation to treat prevalent diseases like hypercholesterolemia, hepatitis B, neurodegeneration, metabolic disorders, and rare diseases.[1][2][3][5] Its proprietary EPIREG™ platform enables precise, durable gene silencing via DNA methylation and histone modification without DNA cleavage, paired with the EpiTax™ in-vivo LNP delivery system for targeted liver and extrahepatic organ delivery, offering safer alternatives to traditional gene editing.[2][3][4] The company serves patients with hard-to-treat chronic conditions, solving issues like off-target effects, short durability, and delivery challenges in gene therapies, with strong growth shown through $52M total funding—including a $32M Series A in 2023 and $60M Series B in 2025—multiple pipeline candidates advancing to clinical stages, and partnerships like Bayer Co.Lab.[1][2][3]
Founded in 2021 by leading scientists specializing in gene editing technologies, Epigenic Therapeutics emerged from expertise in epigenetic regulation to pioneer safer gene modulation therapies.[1][3] Headquartered in Shanghai, China, the company quickly gained traction with its EPIREG™ platform, securing a $32M Series A in 2023 to advance epigenome medicines toward clinics.[1][3] Pivotal moments include non-human primate proof-of-concept data for cholesterol-lowering (published in *Nature Biotechnology* in 2025), entry into investigator-initiated trials (IIT)/IND for leads like EPI-001 (PCSK9 for hypercholesterolemia) and EPI-003 (HBV), and the 2025 Series B to accelerate clinical development.[2][3][5]
Epigenic rides the epigenetic medicine wave, a next frontier in gene therapy amid CRISPR limitations like safety risks and immunogenicity, fueled by rising demand for durable treatments in metabolic/liver diseases (e.g., hypercholesterolemia affecting millions) and HBV (chronic in 250M+ globally).[2][3][4][5] Timing aligns with LNP advances post-mRNA vaccines and 2025 regulatory nods for epigenetic tools, plus China's biotech boom enabling rapid scaling.[1][2][3] Market tailwinds include aging populations driving neurodegeneration/obesity needs and investor focus on non-viral platforms; Epigenic influences the ecosystem via tech partnerships (e.g., Bayer, conference presentations) and publications validating durable silencing in primates, potentially reshaping in-vivo gene modulation standards.[2][3][4]
Epigenic is poised for clinical breakthroughs in 2026+, with EPI-001/003 entering Phase I/II, leveraging NHP data and IIT momentum to challenge incumbents like siRNA therapies.[3][5] Trends like AI-optimized epigenome editing and expanded LNP targeting will amplify its edge, potentially yielding first-in-class approvals by 2028 amid a $50B+ gene therapy market.[2][4] Its influence may grow through global partnerships and platform licensing, transforming chronic disease care—echoing its founding promise of safer, one-time epigenome therapies for unmet needs.[1][3]
Epigenic Therapeutics has raised $112.0M across 3 funding rounds. Most recently, it raised $60.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $60.0M Series B | Zhihua Yu | OrbiMed, IFSC, Qiming Venture Partners |
| Aug 1, 2023 | $32.0M Series A | OrbiMed, Chen Kan | Morningside |
| Aug 8, 2022 | $20.0M Pre-Series A | FountainBridge Capital, Kingray Capital, Michael Xue, Trinity Innovation Fund |